With 13.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 7.68 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3997 whereas the lowest price it dropped to was $0.2715. The 52-week range on ADIL shows that it touched its highest point at $3.00 and its lowest point at $0.22 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 1.02.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ADIL was up-trending over the past week, with a rise of 37.94%, but this was down by -53.82% over a month. Three-month performance dropped to -50.13% while six-month performance fell -69.88%. The stock lost -68.68% in the past year, while it has lost -71.76% so far this year.
Float and Shares Shorts:
At present, 15.78 million ADIL shares are outstanding with a float of 14.42 million shares on hand for trading. On 2025-06-13, short shares totaled 0.49 million, which was 470.0 higher than short shares on 1747267200. In addition to Mr. Cary John Claiborne MBA as the firm’s CEO, President & Director, Mr. Tony Goodman serves as its COO & Director.
Institutional Ownership:
Through their ownership of 0.03642 of ADIL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, ADIL reported revenue of $0.0 and operating income of -$2267293.0. The EBITDA in the recently reported quarter was -$2267152.0 and diluted EPS was -$0.34.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ADIL analysts setting a high price target of 6.0 and a low target of 2.0, the average target price over the next 12 months is 4.0. Based on these targets, ADIL could surge 1775.0% to reach the target high and rise by 525.0% to reach the target low. Reaching the average price target will result in a growth of 1150.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.57418 being high and -$2.97582 being low. For ADIL, this leads to a yearly average estimate of -$2.775.
